Table 1.
Gene Expression in Malignant Relative to Normal Prostate Tissues by Array, RT-PCR and Northern Blot Analysis.
| Gene Symbol | Primer Set* | Expression Pattern (by Array) | Comparison (RT-PCR, Array, Northern) | Clontech Array, T/N Normalized to ACTB¶ | Northern Blot T/N# | Northern Blot T/N for ACTB | Northern Blot T/Nx1/ACTB (Normalized to ACTB)** | Gene Description | |||||
| RT-PCR | |||||||||||||
| Ratio, T/N† | Ratio, T/N† | Ratio, T/N† | Average T/N‡ | Normalized to ACTB (x1.017)§ | |||||||||
| TGFB3 | 4 | ↓ in tumor | consistent | -2.745 | -2.422 | -2.583 | -2.627 | -4.801 | -4.240 | +0.890 | -4.759 | Transforming growth factor-beta 3 | |
| VEGF | 21 | ↓ in tumor | consistent | -6.939 | -6.939 | -6.937 | -2.618 | Vascular endothelial growth factor | |||||
| IGF2 | 20 | ↓ in tumor | consistent | -1.277 | -1.429 | -1.353 | -1.376 | -2.364 | -14.06 | +0.951 | -14.784 | Insulin-like growth factor II | |
| FGF7 | 23 | ↓ in tumor | consistent | -2.1079 | -2.108 | -2.144 | -2.028 | FGF7 | |||||
| MLH1 | 14 | ↓ in tumor | array>rt pcr | +1.593 | +1.376 | +1.485 | +1.510 | -2.133 | MutL (Escherichia coli) homolog 1 | ||||
| MLP | 8 | ↑ in tumor | consistent | +1.290 | +1.271 | +1.299 | +1.287 | +1.309 | +4.082 | +3.460 | +1.225 | +2.825 | MacMarcks |
| MYC | 1 | ↑ in tumor | consistent | +1.406 | +1.764 | +1.585 | +1.612 | +3.509 | +1.577 | +0.855 | +1.845 | c-Myc oncogene | |
| TGFBR3 | 2 | ↑ in tumor | consistent | +1.028 | +1.078 | +1.053 | +1.071 | +3.378 | Transforming growth factor beta receptor III | ||||
| BTEB2 | 15 | ↑ in tumor | consistent | +13.333 | +4.950 | +9.142 | +9.297 | +3.049 | +3.145 | +0.922 | +3.413 | Basic transcription element-binding protein 2 | |
| MGST1 | 11 | ↑ in tumor | consistent | +1.795 | +1.508 | +1.652 | +1.680 | +2.801 | +4.256 | +0.807 | +5.274 | Glutathiones S-transferase 12 | |
| IGFBP2 | 3 | ↑ in tumor | consistent | +1.250 | +1.580 | +1.415 | +1.439 | +2.747 | +2.238 | +0.857 | +2.610 | Insulin-like growth factor binding protein 2 | |
| EPHB3 | 6 | ↑ in tumor | consistent | +1.698 | +3.257 | +2.478 | +2.520 | +2.331 | Tyrosine kinase receptor | ||||
| RFC4 | 13 | ↑ in tumor | consistent | +6.849 | +6.849 | +6.965 | +2.294 | Replication factor C 37-kDa subunit | |||||
| ERBB3 | 16 | ↑ in tumor | consistent | +2.283 | +2.427 | +2.355 | +2.400 | +2.193 | +1.326 | +0.932 | +1.422 | Epidermal growth factor receptor; HER3 | |
| CYP1B1 | 7 | ↑ in tumor | consistent | +1.553 | +3.650 | +2.601 | +2.646 | +2.174 | Dioxin-inducible cytochrome P450 | ||||
| ACTB | 1.270 | 0.820 | 0.860 | 0.983 | 1.000 | Beta actin | |||||||
Identifiers for forward and reverse oligonucleotides used in RT-PCR experiments (consistent with those in Figure 3).
The ratio of the optical densities of RT-PCR products from malignant (T) and normal (N) tissues.
The average of all RT-PCR ratios for a particular gene.
The inverse (1.017) of the average (0.983) of the optical densities of RT-PCR products from malignant (T) and normal (N) tissues for the ACTB gene. All average RT-PCR values were multiplied by 1.017 in order to set T/N to 1.0 for ACTB, and to normalize all other average RT-PCR ratios to ACTB expression.
The ratio of expression levels of malignant (T) /normal (N) tissues for each gene after normalization to ACTB expression by array analysis.
The ratio of the optical densities of transcripts identified using Northern blot analysis for malignant (T) /normal (N) tissues for each gene.
The ratios in the preceding column (#) after multiplication by 1 /ACTB for the purpose of normalization to ACTB expression for each blot.